Athira CEO Kawas: Alzheimer’s Drug Aims for “Recovery of Brain Function”

The key to Athira Pharma’s approach to Alzheimer’s disease is already inside each of us: a repair mechanism that can regenerate damaged neurons. What’s needed to begin the process is a pharmacological kickstart.

Athira (NASDAQ: ATHA) is developing a drug intended to turn on the repair pathway. The company’s experimental therapy is a small molecule that crosses the protective blood-brain barrier to reach its target. Leen Kawas, the founder and CEO of Seattle-based Athira, says that whereas previous drug research efforts aimed to slow the disease’s progression, Athira’s tack offers the potential to reverse the effects of Alzheimer’s.

“We hope... Read more »

Reprints | Share: